# An Evaluation of LY007 Cell Injection for r/r B-NHL

> **NCT06279611** · PHASE1 · RECRUITING · sponsor: **Shanghai Longyao Biotechnology Inc., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- B-NHL

## Interventions

- **DRUG:** LY007

## Key facts

- **NCT ID:** NCT06279611
- **Lead sponsor:** Shanghai Longyao Biotechnology Inc., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-25
- **Primary completion:** 2024-08-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279611, "An Evaluation of LY007 Cell Injection for r/r B-NHL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06279611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*